Biocon Biologics refinances 1.1 billion debt through US dollar bonds and new syndicated facility

The bonds will be issued by Biocon Biologics Global plc which is a wholly owned subsidiary of BBL and will be backed by a strong security package, the company said. The bonds will be issued by Biocon Biologics Global plc which is a wholly owned subsidiary of BBL and will be backed by a strong security package, the company said.  Economic Times